These results are consistent with earlier observations that WEE1 and CHK1 expression levels are associated with cisplatin sensitivity [52], and targeting cell-cycle checkpoints, including ATR, CHK1, and WEE1, can be used to sensitize tumor cells to cisplatin. This evidence concerns the gene WEE1 and neoplasm.